LONN Lonza Group AG

Maria Soler Nunez appointed as Head, Group Operations

Lonza Group AG / Key word(s): Personnel
Maria Soler Nunez appointed as Head, Group Operations

01.07.2022 / 08:00


 
  • Lonza appoints Maria Soler Nunez as Head, Group Operations
  • Maria joins Lonza from Novartis where she has led the quality organization since 2020
  • Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who is retiring from Lonza
 

Basel, Switzerland, 1 July 2022 – Lonza today announced that its Board of Directors has appointed Maria Soler Nunez as the new Head, Group Operations. The appointment will be effective from 1 August 2022. Maria will succeed Stefan Stoffel as a member of the Lonza Group Executive Committee.

Maria joins Lonza Group from Novartis where she has worked since 2010, holding a succession of leadership positions in quality and operations. In her most recent role, Maria led the Novartis quality organization as Chief Quality Officer. In this role, Maria was responsible for all aspects of quality, and was leading an organization of 7,000 associates across preclinical, clinical, TechOps, commercial and Quality Systems functions.

Albert M. Baehny, Chairman, Lonza, commented: “We are looking forward to welcoming Maria to the Lonza Group Executive Committee. Maria’s extensive experience in quality and manufacturing operations will be a great asset as we continue to focus on customer delivery and advance on our ambitious growth journey.”

Pierre-Alain Ruffieux, CEO, Lonza, added: “Maria brings an impressive track record in operations and quality to Lonza. I am greatly looking forward to working with her as we continue our focus on operational excellence and long-term value creation.”

Prior to her most recent role, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology.

Maria holds a graduate degree in Pharmacy Studies and a PhD. in Pharmacy from the Universidad Complutense de Madrid. She also holds a Postgraduate Degree in Design and Statistics for Medical Sciences from the Universidad Autónoma de Barcelona.

Following a handover, Maria will succeed Stefan Stoffel, who has decided to retire. Stefan has held a variety of leadership roles during a career with Lonza spanning more than three decades. Stefan has worked in multiple locations and roles during his extensive career. In his most recent role, Stefan has led Group Operations since January 2021. As a member of the Lonza Group Executive Committee, Stefan has made a valuable contribution to many strategic projects as well as overseeing many important growth and delivery programs that has supported the company’s long-term growth and success.

Stefan will commence his retirement on 1 August, 2022. The Lonza management would like to thank Stefan for his significant contribution during his long tenure and wish him an enjoyable and well-deserved retirement.

 

Notes to editors

A high-resolution image of Maria is available on request from

About Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at

Follow @Lonza on
Follow @LonzaGroup on

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel



End of Media Release


Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone:
Internet:
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1388429

 
End of News EQS News Service

1388429  01.07.2022 

fncls.ssp?fn=show_t_gif&application_id=1388429&application_name=news&site_id=research_pool
EN
01/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lonza Group AG

 PRESS RELEASE

Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon

Lonza Group AG / Key word(s): Bond/Financing Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon 17.04.2024 / 19:00 CET/CEST Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion straight bond. The Eurobond marks Lonza’s second drawdown under its EMTN program. The bond has a maturity of 12 years and an annual coupon of 3.875%. The issuer is Lonza Finance International NV and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Lonza - Upside from Market Disruption (BUY, TP CHF610 [500], 13 pgs)

New analysis of the upcoming disruptions to the biologic CDMO market lead us to upgrade our 2027 Lonza revenues by 10% & our PT to CHF610 (28% upside). We show that recent disruptions to Wuxi & Catalent’s ability to supply the market could mean that 20% of global market CDMO share could be up for grabs. We also show that Lonza inventories have normalised, suggesting a return to normal ordering in 2024. Our AI-derived biologic demand model shows that volume growth should be 12% in 2024 & 2025 and...

Charlotte Vaisse ... (+3)
  • Charlotte Vaisse
  • Oliver Metzger
  • Stephan Wulf

Lonza : Benefiting from the ongoing outsourcing trend in the healthcar...

We are initiating coverage of Lonza with a target price of CHF 535 and an Outperform rating. As one of the world's leading contract development and manufacturing organisations (CDMO), Lonza is predestined to benefit from the sustainable drivers of this industry. The group's global presence and strong market positions in the growth areas of biologics and cell and gene therapy (CGT) will fuel double-digit sales growth and >30% EBITDA margins in the medium term. Despite significant ...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

CDMO - Long Lonza, Short Stedim (LONN: BUY, TP CHF500 [465]; DIM: SELL...

With multiple datapoints, management commentary and peer reporting, we now have a better picture of the H124 outlook and more importantly of how the shares may trade. Whilst company commentary is cautiously optimistic on an H2 revenue recovery, the bottoming of order books and modest growth in sequential sales has led to the market becoming increasingly positive on the Life Science Tools space and CDMO’s. While we believe the risks are still significant, we believe the margin risk is now more ma...

 PRESS RELEASE

Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds

Lonza Group AG / Key word(s): Bond/Financing Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds 06.11.2023 / 18:30 CET/CEST Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche straight-bond issuance in line with its financing plan for 2023. The bonds have a maturity of 4.5 years and 7.5 years respectively with coupons of 2.250% and 2.600%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch